IDH1 and central nervous system cancer: Although they found no mutations in TET2, they identified promoter methylation of TET2 in 5 of 35 low-grade gliomas, whereas low-grade gliomas with IDH1/2 mutations showed no hypermethylation of the TET2 promoter.